11.07.2015 Views

biomedical sciences research institute - Research - University of Ulster

biomedical sciences research institute - Research - University of Ulster

biomedical sciences research institute - Research - University of Ulster

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

McClean PL, Irwin N, Hunter K, Gault VA and Flatt PR; (Pro 3 )GIP[mPEG]: Novel long-acting mini-PEGylated gastricinhibitory polypeptide antagonist for obesity-diabetes therapy; British Journal <strong>of</strong> Pharmacology, 155: 690-701, 2008Taylor A, Irwin N, McKillop AM, Flatt PR and Gault VA; Sub-chronic administration <strong>of</strong> 11beta-HSD1 inhibitor,carbenoxolone, improves glucose tolerance and insulin insensitivity in mice with diet-induced obesity; Biol. Chem.,389: 441-445, 2008Kerr BD, Irwin N, Flatt PR and Gault VA; Prolonged GIP receptor activation using stable mini-PEGylated GIP improvesglucose homeostasis and beta cell function in age-related glucose intolerance; Peptides (in press)Dr JT McCluskeyLecturer in Biomedical SciencesContact details:T: +44 (0)28 70324882jt.mccluskey@ulster.ac.ukBrief pr<strong>of</strong>ile:BSc Hons from <strong>University</strong> <strong>of</strong> Glasgow (1991) and DPhil from <strong>University</strong> <strong>of</strong> Oxford (1995) in Developmental andCellular Biology. Postdoctoral <strong>Research</strong> at King’s College London (1995 – 1997), <strong>University</strong> College London (1997-1998) and <strong>University</strong> <strong>of</strong> <strong>Ulster</strong> (1998 – 2007) prior to taking up present position as Lecturer in Biomedical Sciencesat the <strong>University</strong> <strong>of</strong> <strong>Ulster</strong>, Coleraine (2007). Over 30 peer-reviewed publications and invited speaker at internationaland national conferences.Main <strong>research</strong> interests:• Cellular and molecular events in novel human and rodent insulin-secreting pancreatic beta cell lines• Formation <strong>of</strong> pancreatic endocrine cells from embryonic stem cells• Glucose and lipid toxicity, drug sensitisation, and actions <strong>of</strong> cytotoxic agentsPublications:Liu HK, McCluskey JT, McClenaghan NH, Flatt PR; Streptozotocin-resistant BRIN-BD11 cells possess a wide spectrum<strong>of</strong> toxin tolerance and enhanced insulin-secretory capacity; Endocrine, 32: 20-29, 2007Gault VA, McClean PL, Irwin N, Power GJ, McCluskey JT, Flatt PR; Effects <strong>of</strong> subchronic treatment with the long-actingglucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocininduceddiabetes; Pancreas, 35: 73-79, 2007Patterson S, Scullion SM, McCluskey JT, Flatt PR, McClenaghan NH; Prolonged exposure to homocysteine resultsin dimished but reversible pancreatic beta-cell responsiveness to insulinotropic agents. Diabetes Metab. Res. Rev.,23(4):324-334, 2007Liu HK, McCluskey JT, McClenaghan NH, Flatt PR; Iterative exposure <strong>of</strong> clonal BRIN-BD11 cells to ninhydrin enablesselection <strong>of</strong> robust toxin-resistant cells but with decreased gene expression <strong>of</strong> insulin secretory function; Pancreas,36: 294-301, 2008McClean PL, Gault VA, Irwin N, McCluskey JT, Flatt PR; Daily administration <strong>of</strong> the GIP-R antagonist (Pro3)GIP instreptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity diabetesactions <strong>of</strong> (Pro3)GIP; Diabetes Obes. Metab., 10: 336-342, 200852

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!